What Берлиприл Treats: Main Uses and Benefits

The medication is commonly used to help manage symptoms across key therapeutic domains.

Берлиприл is generally applied across domains where additional symptomatic support is needed for conditions such as hypertension (high blood pressure), symptomatic congestive heart failure, and asymptomatic reduced heart pumping function. The medication is also considered relevant in situations involving symptoms linked to organ-specific functional stress, such as those seen in diabetic and proteinuric chronic kidney disease.

Long-Term Management of Systemic Strain

The medication is commonly used for managing symptoms of chronic high blood pressure, a condition characterized by heightened physiological activity that creates noticeable physiological strain. This supportive therapy is applied in addressing symptoms related to heightened physiological activity, which may contribute to easing the overall physiological strain and assists with maintaining functional stability. For heart-related conditions, it helps address symptom clusters that may become disruptive, such as dyspnea (shortness of breath) and fatigue.

Quick Fact: Supportive Management
Primary Focus: Supportive relief for symptoms related to systemic imbalance and functional strain.
Patient Benefit: Contributes to improved comfort during symptomatic periods and supports general cardiovascular well-being.
Context: Applied in clinical settings that involve chronic or unstable symptom patterns.

The eligibility for using Enalapril Maleate (Берлиприл) is strictly governed by specific population rules documented in regulatory labeling. The medicine is primarily approved for use in adults with conditions such as hypertension and symptomatic heart failure. Use is also established for pediatric patients over one month of age for hypertension, but it is not recommended for neonates or children with severe kidney impairment.

Contraindicated Populations (Must Not Use)

Category	Regulatory Status
Hypersensitivity	Contraindicated in patients with known allergy to Enalapril, any other ACE inhibitor, or tablet components.
Angioedema History	Contraindicated in patients with a history of hereditary, idiopathic, or ACE inhibitor-related angioedema.
Pregnancy Status	Contraindicated during the second and third trimesters of pregnancy, and not recommended during the first trimester.
Combination Therapy	Contraindicated with concomitant use of sacubitril/valsartan (must not be initiated within 36 hours of switching) or with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted or Conditional Use

Patients with pre-existing conditions like renal impairment or hepatic impairment require cautious use and close monitoring. Special supervision is also necessary for patients with bilateral renal artery stenosis and certain heart conditions like severe aortic or mitral valve stenosis due to specific documented risks.

Interactions with other medicines and products

Official regulatory information for Enalapril Maleate (Берлиприл) defines interactions across several key categories, primarily focusing on pharmacodynamic effects and combination restrictions.

Documented Interaction Restrictions

Co-administration with Aliskiren is contraindicated in patients with established Diabetes Mellitus or Renal Impairment (GFR less than 60 mL/min/1.73 m^2). The use of Neprilysin (NEP) Inhibitors with Enalapril is also restricted/contraindicated due to the significantly increased risk of angioedema. The Dual Blockade of the Renin-Angiotensin System (RAS), such as combining Enalapril with an Angiotensin Receptor Blocker (ARB), is generally avoided due to increased risks of hypotension and renal changes.

Pharmacodynamic and Exposure Interactions

Interacting Substance/Class	Official Interaction Description
Diuretics (e.g., Thiazides)	Augments the antihypertensive effect, leading to a risk of excessive symptomatic hypotension.
Potassium Agents (Supplements, Salt Substitutes)	Increases the risk of Hyperkalemia (elevated serum potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Can blunt the blood pressure-lowering effect and increase the risk of deterioration of renal function.
Lithium	Co-administration may increase serum lithium concentrations and the potential for toxicity.

Administration Context and Timing

If a diuretic cannot be discontinued before initiating Enalapril, close medical supervision is required for at least two hours after the initial dose and until blood pressure is stable. Furthermore, the absorption of Enalapril is officially reported as not influenced by the presence of food in the gastrointestinal tract.

Берлиприл, containing the prodrug enalapril maleate, is an orally administered compound. Upon absorption, it undergoes hepatic hydrolysis via carboxylesterase 1 (CES1) to form its active metabolite, enalaprilat.

Enalaprilat functions as a potent, competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), which is a zinc-containing peptidyl dipeptidase. This enzyme is responsible for catalyzing the conversion of the inactive decapeptide angiotensin I to the biologically active octapeptide angiotensin II.

Inhibition of ACE effectively suppresses the renin-angiotensin-aldosterone system (RAAS). The reduction in circulating angiotensin II concentration leads to several intracellular and systemic consequences: decreased activation of the AT1 receptors on vascular smooth muscle cells, resulting in a decline in vasoconstriction. Furthermore, decreased angiotensin II diminishes stimulation of the adrenal cortex, which subsequently reduces the secretion of the mineralocorticoid aldosterone. Reduced aldosterone levels modulate renal distal tubule and collecting duct activity, leading to decreased sodium and water reabsorption and a concurrent increase in potassium retention. ACE inhibition also reduces the degradation of the vasodilator peptide bradykinin, leading to its local accumulation. The combined systemic effect is a decrease in total peripheral vascular resistance and a reduction in circulating blood volume.

How to Use Берлиприл: Administration Guidelines

Берлиприл (Enalapril maleate) is administered according to specific protocols that outline the proper route, dosing, and schedule. This information is designed to standardize the usage of the medication.

---

Route and Form

The route of administration for Берлиприл tablets is oral use. The medication is available as oral tablets in strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg. Administration may be done with or without food, as its absorption is not clinically affected by meals; however, it is generally recommended to take the medication at about the same time each day to maintain consistency.

---

Standard Dosing Protocol

Dosage is individualized and typically involves a titration (gradual adjustment) phase to establish the most appropriate maintenance dose. The dose should not be doubled to compensate for a missed dose.

Indication	Initial Dosing	Frequency	Key Procedural Requirement
Hypertension	5 mg to 10 mg daily	Once daily	Optimal effect may require several weeks of continuous therapy.
Heart Failure	2.5 mg once or twice daily	Once or twice daily	Initial dose is administered under close medical supervision.

---

Population-Specific Adjustments

Specific dose adjustments are applied for patients with impaired kidney function. For adults with moderate to severe renal impairment (creatinine clearance ≤ 30 mL/min), a lower initial dose of 2.5 mg once daily is utilized. Pediatric dosing for hypertension is calculated based on body weight.

Берлиприл: Recent Clinical Evidence

This overview summarizes the type of research that has been conducted for Берлиприл (active ingredient: Enalapril) and outlines the evidence base according to authoritative scientific and regulatory sources. This information describes patterns observed in research settings and should not be used as clinical guidance.

Clinical evidence for the use of Enalapril in managing high blood pressure is extensive, supported by Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies explored outcomes related to the measurement of systolic and diastolic blood pressure, and long-term patterns in cardiovascular events. Research indicates that the measured blood pressure response may vary across different patient groups.

For symptomatic heart failure, evidence is foundational, supported by large, placebo-controlled RCTs (e.g., CONSENSUS, SOLVD Treatment trial). These studies explored outcomes related to all-cause mortality, frequency of hospitalizations, and changes in functional status over observation periods lasting up to several years. Related research also explored the effects in asymptomatic individuals with reduced heart pumping function, examining outcomes related to the rate of symptomatic heart failure onset.

Studies exploring use in organ-specific functional stress, particularly chronic kidney disease in diabetic patients, are often presented through systematic reviews. This research examined outcomes related to disease markers such as changes in serum creatinine doubling and protein excretion. However, comparative evidence is lacking when isolating the findings for Enalapril versus other drug alternatives.

Research has also explored Enalapril in pediatric populations (children aged 6 to 16) for blood pressure outcomes. Data for certain groups remain insufficient, and long-term effects are not fully established for all outcomes in this population. Certainty remains low in some specific areas, and the evidence base often reflects the patterns of the entire drug class (ACE inhibitors).

Common questions about Берлиприл (FAQ)

Q: What is Берлиприл used for?

Берлиприл (Enalapril) is a medication indicated for the management of high blood pressure (hypertension). It may also be used in the management of symptomatic heart failure and for the prevention of symptomatic heart failure in patients with left ventricular dysfunction.

Q: How should I take my Берлиприл?

The correct way to take this medication, including the dose and frequency, is determined solely by a healthcare professional. It is usually taken by mouth with or without food, as prescribed. Patients should follow the specific instructions provided on the prescription label and consult their doctor or pharmacist with any questions regarding administration.

Q: Can I stop taking Берлиприл if my blood pressure improves?

Patients should not stop taking any prescribed medication, including Берлиприл, without first consulting their healthcare provider. Discontinuing treatment suddenly may lead to a rise in blood pressure, which can increase the risk of serious health events. A healthcare professional can determine the appropriate duration and adjustments for treatment.

How to Store and Dispose of Берлиприл

Storage and disposal instructions for Берлиприл (Enalapril maleate) are strictly defined by regulatory labeling to maintain product stability.

Storage Requirements

Requirement	Details
Temperature (Tablets)	Store at Controlled Room Temperature (20 C to 25 C), or below 25 C.
Protection	Store protected from moisture in the original container, kept tightly closed.
Child Safety	Must be stored out of the sight and reach of children.
Oral Solution	Store refrigerated (2 C to 8 C); protect from freezing.

️ Disposal Instructions

Unused or expired medicine must be disposed of according to local/national regulations. It should not be discarded via wastewater or household waste to protect the environment. Return the product to a pharmacy or designated collection point for proper pharmaceutical waste handling.